Navigation Links
WuXi AppTec Welcomes Three Senior Professionals
Date:3/24/2009

SHANGHAI, March 24 /PRNewswire-Asia/ -- WuXi AppTec (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced the addition of three key senior professionals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Dr. Brian J. Xu has joined WuXi AppTec as Vice President of Toxicology and Head of the Safety Evaluation Center at Suzhou, reporting to Dr. Ge Li, Chairman and Chief Executive Officer. Dr. Xu is an American Board Certified Toxicologist (DABT) and had worked previously in Merck, Roche, Schering-Plough and Enzon. Dr. Xu received his Ph.D. from George Washington University and did post-doctoral research at Yale University.

Dr. Yang-Dar Yuan has joined the company as Vice President of Operation and Head of Pathology of the Safety Evaluation Center, reporting to Dr. Brian Xu. Dr. Yuan is a member of American College of Veterinary Pathologists (ACVP), a member of the American College of Laboratory Animal Medicine and an American Board Certified Toxicologist (DABT). He brings more than 30 years of rich experiences in preclinical safety assessment and drug development. Dr. Yuan had worked previously in Upjohn, Pfizer, Allergan and Vitae Pharmaceutical. Dr. Yuan received a D.V.M. from National Taiwan University and a Ph.D. in Veterinary Pathology from Cornell University.

Mr. Robert Coldreck has joined the company as Head of GLP (Good Laboratory Practice) QA (Quality Assurance). Mr. Coldreck had previously worked in Novartis, most recently as Director of Laboratory and Preclinical Quality Assurance-North America and Asia. He brings more than 30 years of rich experience in GLP quality assurance. Mr. Coldreck received his B.S. in Biology from Fairleigh Dickinson University.

"I am delighted to welcome Brian, Yang-Dar and Bob to our management team to lead our preclinical services," said Dr. Li. "With their rich experience and knowledge in GLP preclinical studies and their strong leadership in respective fields, WuXi continues to build a world-class preclinical service platform to serve our customers' demands."

About WuXi AppTec and WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Sherry Shao
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4002
     Email: pr@wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
2. WuXi PharmaTech Completes Acquisition of AppTec
3. WuXi AppTec VP and GM Invited to Join the AAMI Standards Board
4. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
5. WuXi AppTec Selects H-Cube from ThalesNano for Laboratory-based Hydrogenation
6. Professor K. C. Nicolaou Speaks at WuXi AppTec
7. Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
8. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
9. BioSpace Career Fair in San Francisco Welcomes Over 1,000 Bioscience Professionals
10. FCP Welcomes Mark Scherling
11. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
(Date:4/29/2016)... Italy , April 29, 2016 ... 5.11, the latest update to its industry-leading treatment planning ... shown that Monaco version 5.11 ... can now attain calculation speeds up to four times ... . With the industry,s gold standard ...
(Date:4/28/2016)... Boston, MA (PRWEB) , ... April 28, 2016 ... ... (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for ... the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu ... at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable ... metals, and more. Expo attendees can stop by booth 1021 to learn how ...
Breaking Biology Technology:
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... , March 9, 2016 ... government identified that more than 23,000 public service employees ... had been receiving their salary unlawfully.    --> ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... DE SOTO, Kansas , March 3, 2016 /PRNewswire/ ... offer Oncimmune,s Early CDT®-Lung, a blood test to ... lung cancer Early CDT®-Lung test to its ... --> Early CDT®-Lung test to its clients which ... Oncimmune, a leader in early cancer detection, today announced ...
Breaking Biology News(10 mins):